World Investment Advisors Grows Stock Holdings in Johnson & Johnson $JNJ

World Investment Advisors grew its holdings in Johnson & Johnson (NYSE:JNJ) by 19.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 161,343 shares of the company’s stock after acquiring an additional 26,450 shares during the period. World Investment Advisors’ holdings in Johnson & Johnson were worth $33,390,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JNJ. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson during the third quarter worth $26,000. Cresta Advisors Ltd. acquired a new position in Johnson & Johnson during the fourth quarter worth $26,000. DecisionPoint Financial LLC raised its position in Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares during the period. Family CFO Inc acquired a new position in Johnson & Johnson during the fourth quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC raised its position in Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after acquiring an additional 49 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,142 shares of company stock valued at $7,360,528 in the last quarter. 0.16% of the stock is owned by insiders.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J says Tremfya and newly approved Icotyde will anchor its post-Stelara immunology strategy, helping support growth as Stelara faces biosimilar competition.
• Positive Sentiment: The company launched the Shockwave C2 Aero Coronary IVL catheter globally, reinforcing momentum in its medtech division and expanding its cardiovascular portfolio.
• Positive Sentiment: J&J continues to highlight strong Phase 3 TREMFYA data and new neuropsychiatry portfolio results, which could improve confidence in its pipeline and future launches.
• Neutral Sentiment: J&J will participate in the Goldman Sachs Global Healthcare Conference, which may offer investors more color on strategy but is not, by itself, a major fundamental catalyst.
• Neutral Sentiment: Broader market weakness, especially pressure on the Nasdaq from chip stocks, may be influencing overall sentiment, but it is not specific to J&J’s business.

Johnson & Johnson Price Performance

Shares of JNJ opened at $224.44 on Wednesday. Johnson & Johnson has a 1-year low of $146.12 and a 1-year high of $251.71. The stock has a market cap of $540.28 billion, a PE ratio of 25.95, a P/E/G ratio of 2.17 and a beta of 0.27. The firm has a 50-day simple moving average of $236.18 and a two-hundred day simple moving average of $221.21. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter last year, the firm posted $2.77 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a $1.34 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s payout ratio is presently 61.97%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Argus upped their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Citigroup upped their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, April 7th. Rothschild & Co Redburn increased their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Raymond James Financial increased their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Finally, Guggenheim increased their target price on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $252.48.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.